z-logo
open-access-imgOpen Access
Ex vivo Delivery of Suicide Genes into Melanoma Cells Using Epidermal Growth Factor Receptor‐specific Fab Immunogene
Author(s) -
Ohtake Yuichiro,
Chen Jiabing,
Gamou Shinobu,
Takayanagi Atsushi,
Mashima Yukihiko,
Oguchi Yoshihisa,
Shimizu Nobuyoshi
Publication year - 1999
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1999.tb00770.x
Subject(s) - suicide gene , microbiology and biotechnology , thymidine kinase , cytosine deaminase , epidermal growth factor , biology , transfection , reporter gene , genetic enhancement , cancer research , cell culture , chemistry , herpes simplex virus , receptor , virology , gene , virus , gene expression , biochemistry , genetics
The Fab fragment of monoclonal antibody B4G7 against human epidermal growth factor (EGF) receptor was conjugated with cationic poly‐ l ‐lysine and the resulting conjugate was further complexed with reporter genes or therapeutic genes. This Fab/DNA complex was designated as “Fab immunogene”. The Fab immunogene transfer in vitro was mediated through the EGF receptors in two melanoma cell lines. The frequency of cells expressing β‐galactosidase ( β‐Gal ) reporter gene was approximately 1%. The induction of suicide effects after Fab immunogene transfer of herpes simplex virus thymidine kinase ( TK ) or Escherichia coli cytosine deaminase ( CD ) gene was quite remarkable, and the growth of melanoma cells was inhibited for over 7 days in the presence of ganciclovir (GCV) or 5‐fluorocytosine (5‐FC). Similarly, when melanoma cells treated in vitro with the Fab immunogene carrying TK or CD were transplanted into the back of nude mouse, subsequent systemic administration of GCV or 5‐FC effectively suppressed the growth of tumors, indicating the occurrence of in vivo suicide effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here